PMA (premarket approval) review times continue to fall in the US
This article was originally published in Clinica
The FDA has reduced further the time it takes to process applications to market medical devices in the US. In fiscal year 1998, which ended on September 31, the average review time for premarket approval applications (PMAs) from submission to approval fell to 12.4 months, a substantial 25% reduction on the 16.6 month average in 1997 and 50% less than the average of 25.9 months in 1996.
You may also be interested in...
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.